Folding abnormalities of the triple helix have been demonstrated in collagen diseases such as osteogenesis imperfecta in which the mutation leads to the substitution of a single Gly in the (Gly-X-Y) n sequence pattern by a larger residue. Model peptides can be used to clarify the details of normal collagen folding and the consequences of the interruption of that folding by a Gly substitution. NMR and CD studies show that placement of a (GPO) 4 nucleation domain at the N terminus rather than the C terminus of a native collagen sequence allows the formation of a stable triple helix but alters the folding mechanism. Although C-to N-terminal directional folding occurs when the nucleation domain is at the C terminus, there is no preferential folding direction when the nucleation domain is at the N terminus. The lack of zipper-like directional folding does not interfere with triple-helix formation, and when a Gly residue is replaced by Ser to model an osteogenesis imperfecta mutation, the peptide with the N-terminal (GPO) 4 domain can still form a good triple helix N-terminal to the mutation site. These peptide studies raise the possibility that mutant collagen could fold in a C to N direction in a zipper-like manner up to the mutation site and that completion of the triple helix N-terminal to the mutation would involve an alternative mechanism.
Folding abnormalities of the triple helix have been demonstrated in collagen diseases such as osteogenesis imperfecta in which the mutation leads to the substitution of a single Gly in the (Gly-X-Y) n sequence pattern by a larger residue. Model peptides can be used to clarify the details of normal collagen folding and the consequences of the interruption of that folding by a Gly substitution. NMR and CD studies show that placement of a (GPO) 4 nucleation domain at the N terminus rather than the C terminus of a native collagen sequence allows the formation of a stable triple helix but alters the folding mechanism. Although C-to N-terminal directional folding occurs when the nucleation domain is at the C terminus, there is no preferential folding direction when the nucleation domain is at the N terminus. The lack of zipper-like directional folding does not interfere with triple-helix formation, and when a Gly residue is replaced by Ser to model an osteogenesis imperfecta mutation, the peptide with the N-terminal (GPO) 4 domain can still form a good triple helix N-terminal to the mutation site. These peptide studies raise the possibility that mutant collagen could fold in a C to N direction in a zipper-like manner up to the mutation site and that completion of the triple helix N-terminal to the mutation would involve an alternative mechanism.
Abnormalities in protein folding have been shown to play a role in many diseases, including neurodegenerative diseases, cystic fibrosis, and type II diabetes (1, 2) . Protein misfolding also occurs in collagen, in which mutations in the repetitive Gly-X-Y sequence result in a variety of connective tissue diseases. Osteogenesis imperfecta (OI) 1 results from mutations in type I collagen, the major collagen in bone and tendon, whereas Ehlers-Danlos syndrome type IV results from mutations in type III collagen, and Alport's syndrome is caused by mutations in type IV collagen of basement membranes (3). The best characterized disease is OI, which presents with a wide range of clinical phenotypes involving fragile bones, depending on the nature and site of the mutation in type I collagen (4, 5) .
The folding of type I collagen has been extensively characterized and provides a basis for understanding connective tissue folding diseases (4, 6 -8) . In vivo, type I collagen molecules are synthesized in a procollagen form, in which the C-terminal globular propeptides are responsible for chain selection and trimerization. Post-translational hydroxylation of Pro to Hyp residues occurs while the chains are unfolded, which is necessary for triple-helix formation to commence. A distinctive (GlyPro-Hyp) 5 sequence at the C terminus of the triple-helix domain of the ␣1 and ␣2 chains of type I collagen is likely to be involved in the nucleation of the triple helix (6, 9 -11). Following nucleation, the triple-helix conformation is propagated in a zipper-like mechanism from the C to N terminus at a rate limited by cis-trans isomerization of imino acid bonds (6, 9, 12) .
Folding of type I collagen is delayed when an OI mutation is present (7, 8) . The most common mutations are single base changes leading to a Gly substitution that breaks the Gly-X-Y repeating pattern in the triple-helix sequence. Replacement of a single Gly residue by another amino acid anywhere along the ␣1(I) or ␣2(I) chain of type I collagen disrupts the close packing of the three chains and triggers events that lead to defective mineralization of bones (8) . Enzymatic digestion studies (7) show that OI mutations result in slower collagen folding rates. In addition, overhydroxylation of Lys residues is observed. Because enzymatic post-translational modifications occur only in the unfolded state, a folding delay at the mutation site would present an increased period of time for the enzyme to act on Lys residues before they adopt a triple-helix structure (8) .
To better characterize folding in normal and mutated collagens, small peptide models of specific collagen regions are studied by CD and NMR (13) . Collagen sequences with or without Gly replacement mutations can be incorporated into triple helical peptides as long as stabilizing Gly-Pro-Hyp units are included (14) . Peptide T1-892, a 30-mer, contains a Cterminal (Gly-Pro-Hyp) 4 sequence, modeling the nucleation domain of type I collagen, and an N-terminal sequence of residues 892-909 from the ␣1(I) chain of type I collagen (GPAGPAG-PVGPAGARGPA). Previous studies (12) have shown that peptide T1-892 adopts a stable triple helix with folding initiated at the C terminus (Gly-Pro-Hyp) 4 , which models the directional folding of collagen and provides a system for investigating the consequences of Gly substitutions.
Possible folding models for the rod-like collagen triple helix are limited by the linear nature of the conformation. The cur-rent paradigm for native triple-helix folding assumes a single C-terminal nucleation event followed by zipper-like, unidirectional folding (6, 12, 15) . Here, the possibility of triple-helix formation and the nature of the folding were investigated when the (GPO) 4 nucleation domain was switched from the C to the N terminus in peptide T1-892. Interestingly, the directional nature of folding was lost when the nucleation took place at the N terminus, but a stable triple helix was formed. Previously, peptides have modeled the folding interference caused by a mutation, such as the failure of T1-892 peptides with Gly replacements to propagate through a Gly to X mutation site (16) . To better understand what takes place at the N terminus of the mutation site, the effect of a Gly to Ser replacement in the peptide with the N-terminal (GPO) 4 nucleation domain was also characterized.
EXPERIMENTAL PROCEDURES
CD Measurements-All peptides were manually synthesized by SynPep Corp. (Dublin, CA) on an Fmoc-RINK (where Fmoc is N-(9-fluorenyl)methoxycarbonyl) resin using solid-phase peptide synthesis procedures (17) . The purity and identity of the peptide were confirmed using reversed phase analytical high pressure liquid chromatography (C-18 column) and by matrix-assisted laser desorption ionization time-offlight mass spectrometry. CD spectra were recorded on Aviv models 62DS and 202-01 spectrometers, with a Peltier thermoelectric temperature controller. Samples were prepared at a concentration of 1.0 or 0.4 mg/ml, with peptides dried in vacuo over P 2 O 5 for 48 h prior to weighing. Final concentrations were determined by the absorption at 214 nm (assuming ⑀ ϭ 2.2 ϫ 10 3 ). Peptides in 0.15 M NaCl, 0.01 M sodium phosphate, pH 7.0, were equilibrated at 4°C for more than 48 h prior to analysis. Wavelength scans were collected from 210 to 260 nm at 5°C. For melting transitions, the ellipticity at 225 nm was monitored at a rate of 0.3°C/min, with a 2-min equilibration time. For folding studies, peptides were heated to 70°C and then cooled to 5°C to initiate refolding, and the ellipticity at 225 nm was monitored. Data were collected every 5 s, with an averaging time of 5 s over 3 h. Because the data did not fit well to simple first, second, or third order kinetics, an empirical measurement of folding, t1 ⁄2 (the length of time to reach fraction folded ϭ 0.5), was used to compare samples.
NMR Spectroscopy-The peptide solutions for NMR experiments were prepared with 10% D 2 O, 90% H 2 O, pH 2.5. NMR experiments were performed on a Varian Inova 600-MHz spectrometer equipped with a triple resonance probe and pulsed field gradient. Two-dimensional data sets were processed on a Silicon Graphics work station using FELIX 97 (Molecular Simulation, Inc.). Heteronuclear single quantum coherence (HSQC) spectroscopy spectra were recorded at 10°C. 1 H-15 N heteronuclear NOE and folding experiments were performed as described previously (12). For folding experiments, the sample was denatured outside of the NMR spectrometer by heating to 50°C for 5 min and then immersed in an ice-water bath for 20 s to quickly reduce the temperature to 10°C. A series of two-dimensional 1 H- 15 N HSQC spectra were acquired every 3 min at 10°C. The dead time of the first spectrum was 60 s. Kinetics of folding were monitored by measuring cross-peak volumes as a function of time. The folding experiment was repeated three times, and average intensities were used in the analysis. Normalization of monomer and trimer residues was performed as described previously (12). Residue-specific t1 ⁄2 times for the monomer decay were estimated as the time at which the monomer intensity reached the average value between time 0 and the equilibrium value.
RESULTS
Peptide Design-Triple helical peptides were designed with two domains. One domain models the unique C-terminal (GlyPro-Hyp) 4 nucleation sequence, and the other domain is a block of 18 residues (892-910) from the ␣1 chain of type I collagen. Placement of the nucleation (GPO) 4 domain C-terminal to the 892 sequence resulted in peptide T1-892, which has been studied extensively (12). Here this peptide will be referred to as T1-892c to emphasize the location of the nucleation domain at the C terminus (Fig. 1) . Placement of the nucleation domain N-terminal to the 892 sequence results in a peptide denoted as T1Ј-892n. The sequences within the two domains are numbered independently, and the residues within the two domains are differentiated from T1-892c by numbering with primes (Fig. 1) . The central regions of both peptides have identical sequences and differ only in the location of the (Gly-Pro-Hyp) 4 cap. A homologous set of peptides was synthesized with Gly to Ser substitutions at the position corresponding to an OI substitution at G901S in ␣1(I) (Fig. 1) . Peptide T1-892c-G10S contains a Gly 3 Ser replacement at position 10, and peptide T1Ј-892n-G10S contains a Gly 3 Ser replacement at position 10Ј.
CD Stability and Folding-CD spectroscopy was used to investigate the conformation, stability, and folding of these peptide sets. Peptides T1Ј-892n and T1-892c adopt a triple helical conformation at low temperature as seen by the characteristic CD spectrum with a maximum near 225 nm. The CD thermal transitions of T1-892c and T1Ј-892n are indistinguishable, with melting temperatures of 26°C (Fig. 2a) . This indicates that triple-helix stability is independent of the position of the Gly-Pro-Hyp units. Folding that was initiated by a decrease in temperature from 70 to 5°C indicated that peptide T1-892c folded slightly faster than T1Ј-892n at concentrations of both 1 mg/ml ((t1 ⁄2 ϳ1600 s compared with t1 ⁄2 ϳ1800 s) (Fig. 2b) and 0.4 mg/ml (t1 ⁄2 ϳ3525 s compared with t1 ⁄2 ϳ4850 s). The concentration dependence of the folding rate reflects the third order nucleation step, which plays a rate-limiting role at relatively low concentrations.
Both peptides with Gly to Ser replacements showed triple FIG. 1. Sequences for peptides T1-892c, T1-892n, T1-892c-G10S, and T1-892n-G10S. T1-892c, described previously as T1-892 (12), has been renamed to emphasize the C-terminal location of (GPO) 4 domain in contrast to T1-892n. The two domains, the (GPO) 4 nucleation domain at the C-terminal end and a block of 18 residues (892-910) from the ␣1 chain of type I collagen, are numbered independently; the numbers for the (GPO) 4 domain are in brackets. Peptide T1Ј-892n results from placement of the nucleation domain N-terminal to the 892 sequence, and in this peptide the residues are numbered with primes to distinguish them from the residues in T1-892c. Peptides T1-892c-G10S and T1Ј-892n-G10S are homologous to peptides T1-892c and T1Ј-892n, respectively, but contain a Gly 3 Ser replacement at position 10 and 10Ј, respectively. In all peptides the (GPO) 4 nucleating region is shown in gray.
helical CD spectra but with decreased triple-helix content and stability. Peptide T1-892c-G10S was previously shown to have a decreased CD maximum at 225 nm compared with the parent peptide (mean residue ellipticity 1600 deg⅐cm 2 ⅐dmol Ϫ1 reduced from 3000 deg⅐cm 2 ⅐dmol Ϫ1 ) and a stability decreased from 26 to 15.8°C (17) . Peptide T1Ј-892n-G10S also showed a decrease in the characteristic CD maximum at 225 nm, from 3000 deg⅐cm 2 ⅐dmol Ϫ1 to 1850 deg⅐cm 2 ⅐dmol Ϫ1 . Again, the replacement of a Gly by a Ser caused a significant decrease in stability from T m ϭ 26°C to an even lower value, T m ϭ 13.8°C.
NMR Assignments, Dynamics, and Folding of Peptides T1-892c and T1Ј-892n-NMR HSQC spectra of T1Ј-892n showed resonances analogous to those reported for T1-892c. Each labeled residue gave rise to peaks that could be assigned to monomer and trimer forms (12, 16) (Fig. 3, a and c) . For example, in T1-892c, three distinctive peaks, designated Gly-13 T (Fig. 3, a and c, G13 T ) were assigned to the Gly-13 residues in the three chains of the trimer form, and a corresponding set of three peaks with the same chemical shifts (G13Ј T ) can be seen for peptide T1Ј-892n. Similar correspondences were noted for the monomer peaks Gly-13 M /Gly-13Ј M and the trimer and monomer peaks of Ala-6/Ala-6Ј. The labeled Gly in the Cterminal cap region of T1-892c (G [7] ) showed similar trimer and monomer chemical shifts to the labeled Gly in the Nterminal cap region of T1Ј-892n (G[7Ј] ). This indicates that the chemical shift of the labeled position reflects the local chemical environment rather than the residue position with respect to the N and C termini.
Heteronuclear NOE experiments were performed to assess the local dynamics on the picosecond-nanosecond time scale for specific residues in both peptides (Fig. 3, b and d) . The NOEs are positive for all residues studied and are of similar magnitude. This indicates that peptides T1-892c and T1Ј-892n are rigid along their entire lengths, suggesting that the placement of the GPO cap does not affect the conformation and dynamics on the fast picosecond-nanosecond time scale.
NMR experiments were used to monitor real time triplehelix folding, and half-times were calculated from the kinetic data (Table I) . Previous NMR studies (12) indicate a C-to N-terminal folding direction for T1-892c, with Gly- [7] in the Gly-Pro-Hyp cap folding first followed by Gly-13 and Ala-6. The half-times calculated for specifically labeled residues in peptide T1-892c increase in a C-to N-terminal direction, supporting the directional folding. In contrast, when the GPO cap is placed at the N terminus in peptide T1Ј-892n, folding is no longer in the C-to N-terminal direction. The half-times for the three labeled residues are then very similar to each other, indicating no clear preference in directionality of folding.
NMR Assignments and Dynamics of OI Model PeptidesPreviously it was reported that the replacement of the Gly-10 residue by Ser in T1-892c resulted in an asymmetric perturbation of the structure. The (GPO) 4 at the C-terminal end of the peptide and the Gly-13 residue C-terminal to the Ser site retain a triple-helix structure. The Ala-6 residue N-terminal to the Ser substitution site and at the Ser exhibits the mobility of a random chain (Fig. 4, a-c) (16) , supporting a peptide conformation that is only partially triple helical. Similar conformation and dynamics studies were carried out on peptide T1Ј-892n with a Gly to Ser replacement at position 10 (T1Ј-892n-G10S), at which point the (GPO) 4 nucleation domain is at the N terminus (Fig. 4, d-f) . In this case, the Gly-[7Ј] in the N-terminal (GPO) 4 domain and the Ala-6Ј residue N-terminal to the Ser site form a rigid triple helix as supported by distinctive trimer and monomer chemical shifts and positive NOE values. For residue Gly-13Ј located C-terminal to the Ser, the three distinct trimer peaks are lost, and overlapped monomer and trimer peaks with NOE values close to 0 are observed. This supports the presence of some trimer but with a significant loss of rigidity and triple-helix nature C-terminal to the Ser mutation site. Thus, the T1Ј-892n-G10S molecule appears to be partially folded, with a rigid triple helix only N-terminal to the mutation site (Fig. 4, d-f) . DISCUSSION An understanding of triple-helix folding is important for collagen diseases, in which abnormal folding has been observed as a result of Gly substitution mutations (8) . The observation of overmodification of Lys residues at sequences N-terminal to mutation sites reflects the C to N directionality of type I collagen folding and a folding delay at the mutation site. To further investigate triple-helix folding, peptides were designed with strong nucleating triple-helix sequences at the N or C terminus. Both T1-892c and T1Ј-892n form stable triple helices and have the same stability regardless of whether the GPO is on the N or C terminus. This suggests that the stability of peptide models can be attributed to independent contributions of the tripeptide units in the sequence.
Even though both peptides form well folded triple helices with the same stability, T1-892c folds in a C to N direction, whereas T1Ј-892n does not show any preference in folding direction. An initial hypothesis would have been that the location of the nucleation site determines directionality; that is, if (GPO) 4 is at the C terminus, there is C to N zipper-like folding, whereas if (GPO) 4 is at the N terminus, there would be N-to C-terminal zipper-like folding. The studies reported here show this hypothesis is not true for the T1-892 model peptide system. This suggests that there is some inherent asymmetry in the triple helix that promotes directional folding only in the C-to N-terminal direction and only when the strong nucleation sequence is at the C terminus. In the absence of a strong Cterminal nucleation site, triple-helix formation follows a different mechanism with no clear directionality. This nondirectional folding mechanism still can lead to a triple helix, but the overall folding appears to be slower.
The use of triple-helix (Gly-Pro-Hyp) 4 nucleating domains complements recent reports (18 -20) using non-triple-helix domains as nucleation sites for collagen or model peptides. Disulfide bonds or foldons at either the C or N terminus can act as nucleation sites for model collagen peptides (18, 19) . Coiled coil domains at either end have been shown to promote trimerization and folding and are widely used in the assembly of collagen (21) . Thus, the presence of non-collagenous nucleation domains at either end of a triple helix in collagens can support triplehelix formation, although the nature of the folding when there 15 N HSQC spectra are shown at 10°C for T1-892c (a) and T1Ј-892n (c). The sequences for the peptides are shown at the top of a and c, with the 15 N-labeled positions underlined. In the spectrum, monomer and trimer peaks are denoted as superscripts M and T, respectively. The HSQC spectrum for T1-892n is a superposition of spectra obtained from two peptides with differently labeled positions (16) . Heteronuclear 1 H-15 N NOE data for T1-892c (b) and T1Ј-892n (d) are shown. For ease of comparison in the NOE, we have presented data only for Ala-6, Gly-13, and Gly- [7] in T1-892n, although residue Gly-10 is labeled (G10 M , G10 T ) as well.
is N-terminal nucleation has not been characterized. There is evidence that the triple-helix sequence plays a critical role in folding initiation as well (22) (23) (24) . The unique (GPO) 5 sequence at the C terminus of the type I collagen triple helix and the required GPO triplets at the C terminus of type III collagen are two examples. Whereas a non-triple helical nucleation domain, such as a coiled coil or disulfide bond, models an external initiation event, the use of a (Gly-X-Y) n nucleating sequence raises the possibility of internal nucleation events in the collagen sequence. Because previous peptide studies (16) indicate that the C-to N-terminal propagation stops at a Gly to X mutation, with triple-helix structure only C-terminal to the mutation site, it has been suggested that renucleation may be required N-terminal to a Gly to X mutation site in order for full-length collagen to form. The ability of peptide T1Ј-892nЈ-G10S to form a N-terminal rigid triple helix presents a plausible model for independent formation of a triple helix N-terminal to a mutation site (Fig. 4, c and f) . The C-terminal (Gly-Pro-Hyp) n sequence is likely to serve as the primary nucleation site, initi- FIG. 4 . NMR spectra and relaxation data for T1-892c-G10S and T1-892n-G10S. 1 H-15 N HSQC spectra are shown at 10°C of T1-892c-G10S (a) and T1Ј-892n-G10S (d), with monomer and trimer peaks labeled with superscripts M and T, respectively. Heteronuclear 1 H-15 N NOE data for T1-892-G10S (b) and T1Ј-892n-G10S (e) are shown. Schematic diagrams of the conformation of T1-892c-G10S (c) and T1Ј-892n-G10S (f) are shown.
ating the C-to N-terminal folding, but following the termination of propagation at a mutation site, independent nucleation events N-terminal to the mutation site may be facilitated at Hyp-rich sequences farther downstream in the collagen sequence to complete triple-helix formation (8) .
